Literature DB >> 15754293

Increased expression of claudins in cervical squamous intraepithelial neoplasia and invasive carcinoma.

Gábor Sobel1, Csilla Páska, István Szabó, András Kiss, Anna Kádár, Zsuzsa Schaff.   

Abstract

Claudins (CLDNs), of which 24 types have been identified, are integral transmembrane proteins of the tight junctions that are critical for maintaining cell adhesion and polarity. They also act as selective barriers. Cells and tissues are characterized by individual CLDN patterns; the composition and levels of expression change during differentiation and tumor formation. Alterations in the expression of individual CLDNs have been detected in several carcinomas and shown to be related to progression and invasion; however, their role in carcinogenesis is controversial. Using a panel of polyclonal (CLDNs 1, 3, and 7) and monoclonal (CLDNs 2 and 4) antibodies, CLDN pattern and expression were studied by immunohistochemistry in 105 cervical tissue specimens, including normal epithelia (n = 20), cervical intraepithelial neoplasias (CINs; CIN 1/2, n = 27; CIN 3, n = 10), carcinoma in situ (CIS, n = 15), and 33 squamous keratinizing and nonkeratinizing invasive carcinomas. No CLDN 3 was observed in normal or intraepithelial neoplastic cells, but significantly increased expression of CLDNs 1, 2, 4, and 7 was detected in the CIN/CIS lesions and invasive carcinomas compared with the normal tissues (P < .001) and reduced reactivity of CLDNs 1 and 2 was observed in invasive cervical cancers compared with CIN 3/CIS (P = .0001) and of CLDNs 2, 4, and 7 compared with CIN 1/2. These results indicate increased expression of CLDNs in the early phase of carcinogenesis in intraepithelial lesions, which decreases during progression to invasive disease. Expression of CLDN 1 was strongest in premalignant stages; thus, it may serve as a good diagnostic marker for the detection of CIN.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15754293     DOI: 10.1016/j.humpath.2004.12.001

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  36 in total

1.  Claudin expression in Barrett's esophagus and adenocarcinoma.

Authors:  Hajnalka Gyõrffy; Agnes Holczbauer; Pál Nagy; Zsuzsa Szabó; Péter Kupcsulik; Csilla Páska; János Papp; Zsuzsa Schaff; András Kiss
Journal:  Virchows Arch       Date:  2005-08-30       Impact factor: 4.064

2.  Claudin-4 overexpression in epithelial ovarian cancer is associated with hypomethylation and is a potential target for modulation of tight junction barrier function using a C-terminal fragment of Clostridium perfringens enterotoxin.

Authors:  Babak Litkouhi; Joseph Kwong; Chun-Min Lo; James G Smedley; Bruce A McClane; Margarita Aponte; Zhijian Gao; Jennifer L Sarno; Jennifer Hinners; William R Welch; Ross S Berkowitz; Samuel C Mok; Elizabeth I O Garner
Journal:  Neoplasia       Date:  2007-04       Impact factor: 5.715

3.  Tumor-specific marker genes for intrahepatic cholangiocarcinoma: utility and mechanistic insight.

Authors:  Boris Blechacz; Gregory J Gores
Journal:  J Hepatol       Date:  2008-05-22       Impact factor: 25.083

4.  Expression of Tight Junction Components in Hepatocyte-Like Cells Differentiated from Human Embryonic Stem Cells.

Authors:  Boglárka Erdélyi-Belle; György Török; Ágota Apáti; Balázs Sarkadi; Zsuzsa Schaff; András Kiss; László Homolya
Journal:  Pathol Oncol Res       Date:  2015-04-07       Impact factor: 3.201

5.  Gene expression profile regulated by the HPV16 E7 oncoprotein and estradiol in cervical tissue.

Authors:  Enoc M Cortés-Malagón; José Bonilla-Delgado; José Díaz-Chávez; Alfredo Hidalgo-Miranda; Sandra Romero-Cordoba; Aykut Uren; Haydar Celik; Matthew McCormick; José A Munguía-Moreno; Eloisa Ibarra-Sierra; Jaime Escobar-Herrera; Paul F Lambert; Daniel Mendoza-Villanueva; Rosa M Bermudez-Cruz; Patricio Gariglio
Journal:  Virology       Date:  2013-09-27       Impact factor: 3.616

Review 6.  Roles of the first-generation claudin binder, Clostridium perfringens enterotoxin, in the diagnosis and claudin-targeted treatment of epithelium-derived cancers.

Authors:  Yosuke Hashimoto; Kiyohito Yagi; Masuo Kondoh
Journal:  Pflugers Arch       Date:  2016-09-15       Impact factor: 3.657

7.  Claudins 1, 2, 3, 4, 5 and 7 in solar keratosis and squamocellular carcinoma of the skin.

Authors:  Hanna-Riikka Hintsala; Maria Siponen; Kirsi-Maria Haapasaari; Peeter Karihtala; Ylermi Soini
Journal:  Int J Clin Exp Pathol       Date:  2013-11-15

8.  Claudins 1, 3, and 4 protein expression in ER negative breast cancer correlates with markers of the basal phenotype.

Authors:  Anne A Blanchard; George P Skliris; Peter H Watson; Leigh C Murphy; Carla Penner; Ladislav Tomes; Tamara L Young; Etienne Leygue; Yvonne Myal
Journal:  Virchows Arch       Date:  2009-04-23       Impact factor: 4.064

9.  Lgl2 executes its function as a tumor suppressor by regulating ErbB signaling in the zebrafish epidermis.

Authors:  Sven Reischauer; Mitchell P Levesque; Christiane Nüsslein-Volhard; Mahendra Sonawane
Journal:  PLoS Genet       Date:  2009-11-13       Impact factor: 5.917

10.  Claudin-containing exosomes in the peripheral circulation of women with ovarian cancer.

Authors:  Jianghong Li; Cheryl A Sherman-Baust; Miyun Tsai-Turton; Robert E Bristow; Richard B Roden; Patrice J Morin
Journal:  BMC Cancer       Date:  2009-07-20       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.